Xenetic Biosciences Statistics

Total Valuation

XBIO has a market cap or net worth of $6.41 million. The enterprise value is -$1.41 million.

Market Cap	6.41M
Enterprise Value	-1.41M

Important Dates

The next estimated earnings date is Friday, August 9, 2024, before market open.

Earnings Date	Aug 9, 2024
Ex-Dividend Date	n/a

Share Statistics

XBIO has 1.54 million shares outstanding. The number of shares has increased by 1.58% in one year.

Shares Outstanding	1.54M
Shares Change (YoY)	+1.58%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	19.05%
Owned by Institutions (%)	1.27%
Float	1.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.62
Forward PS	3.43
PB Ratio	0.74
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.69, with zero debt.

Current Ratio	11.69
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -43.40% and return on invested capital (ROIC) is -56.11%.

Return on Equity (ROE)	-43.40%
Return on Assets (ROA)	-40.00%
Return on Capital (ROIC)	-56.11%
Revenue Per Employee	$611,240
Profits Per Employee	-$1.12M
Employee Count	4
Asset Turnover	0.22
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +5.91% in the last 52 weeks. The beta is 2.30, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.30
52-Week Price Change	+5.91%
50-Day Moving Average	3.97
200-Day Moving Average	3.81
Relative Strength Index (RSI)	52.43
Average Volume (20 Days)	7,405

Short Selling Information

The latest short interest is 8,609, so 0.56% of the outstanding shares have been sold short.

Short Interest	8,609
Short Previous Month	10,542
Short % of Shares Out	0.56%
Short % of Float	0.73%
Short Ratio (days to cover)	2.01

Income Statement

In the last 12 months, XBIO had revenue of $2.44 million and -$4.47 million in losses. Loss per share was -$2.93.

Revenue	2.44M
Gross Profit	2.44M
Operating Income	-4.87M
Pretax Income	-4.47M
Net Income	-4.47M
EBITDA	-4.47M
EBIT	-4.47M
Loss Per Share	-$2.93

Full Income Statement

Balance Sheet

The company has $7.82 million in cash and no debt, giving a net cash position of $7.82 million or $5.08 per share.

Cash & Cash Equivalents	7.82M
Total Debt	n/a
Net Cash	7.82M
Net Cash Per Share	$5.08
Equity (Book Value)	8.68M
Book Value Per Share	5.63
Working Capital	7.66M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-4.17M
Capital Expenditures	n/a
Free Cash Flow	-4.17M
FCF Per Share	-$2.71

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -199.14% and -182.95%.

Gross Margin	100.00%
Operating Margin	-199.14%
Pretax Margin	-182.95%
Profit Margin	-182.95%
EBITDA Margin	-182.95%
EBIT Margin	-182.95%
FCF Margin	-170.60%

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.58%
Shareholder Yield	-1.58%
Earnings Yield	-69.79%
FCF Yield	-65.08%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

XBIO has an Altman Z-Score of -23.94 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-23.94
Piotroski F-Score	2